Literature DB >> 12763681

Human natural killer cell function and their interactions with dendritic cells.

Lorenzo Moretta1, Guido Ferlazzo, Maria Cristina Mingari, Giovanni Melioli, Alessandro Moretta.   

Abstract

Natural killer (NK) cells have long been considered as "primitive" and "non-specific" effector cells. However, the past 10 years have witnessed dramatic progress in our understanding of how NK cells function and their role in innate defenses. Thanks to specialized inhibitory receptors specific for MHC-class I molecules, they can sense the decrease or loss of these molecules, a typical condition of potentially dangerous cells such as tumor or virally-infected cells. NK cell triggering and lysis of these cells is mediated by several activating receptors and co-receptors that have recently been identified and cloned. While normal cells are usually resistant to the NK-mediated attack, a remarkable exception is represented by dendritic cells (DC). In their immature form (iDC), they are susceptible to NK-mediated lysis because of the expression of low levels of surface MHC-class I molecules. Since the process of DC maturation (mDC) is characterized by the surface expression of high levels of MHC-class I molecules, mDC become resistant to NK cells. Exposure to live bacteria induces rapid DC maturation and, thus, resistance to NK cells. The cross-talk between DC and NK cells is more complex and involves also a DC-dependent NK cell activation and proliferation. Thus, two important players of the innate immunity may be involved in a coordinated regulation of critical events occurring at the interface between innate and adaptive immunity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12763681     DOI: 10.1016/s0264-410x(03)00197-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  CD56bright NK IL-7Rα expression negatively associates with HCV level, and IL-7-induced NK function is impaired during HCV and HIV infections.

Authors:  Chelsey J Judge; Lenche Kostadinova; Kenneth E Sherman; Adeel A Butt; Yngve Falck-Ytter; Nicholas T Funderburg; Alan L Landay; Michael M Lederman; Scott F Sieg; Johan K Sandberg; Donald D Anthony
Journal:  J Leukoc Biol       Date:  2017-04-11       Impact factor: 4.962

Review 2.  The balancing act: inhibitory Ly49 regulate NKG2D-mediated NK cell functions.

Authors:  Subramaniam Malarkannan
Journal:  Semin Immunol       Date:  2006-06       Impact factor: 11.130

3.  Targeted delivery of murine IFN-gamma using a recombinant fowlpox virus: NK cell recruitment to regional lymph nodes and priming of tumor-specific host immunity.

Authors:  Hasan Zeytin; Eva Reali; David A Zaharoff; Connie J Rogers; Jeffrey Schlom; John W Greiner
Journal:  J Interferon Cytokine Res       Date:  2008-02       Impact factor: 2.607

4.  Natural killer cell distribution and trafficking in human tissues.

Authors:  Paolo Carrega; Guido Ferlazzo
Journal:  Front Immunol       Date:  2012-11-29       Impact factor: 7.561

Review 5.  Familial and acquired hemophagocytic lymphohistiocytosis.

Authors:  Gritta E Janka
Journal:  Eur J Pediatr       Date:  2006-12-07       Impact factor: 3.860

Review 6.  Vitamin D Modulation of the Innate Immune Response to Paediatric Respiratory Pathogens Associated with Acute Lower Respiratory Infections.

Authors:  Amy S Bleakley; Paul V Licciardi; Michael J Binks
Journal:  Nutrients       Date:  2021-01-19       Impact factor: 5.717

7.  Stimulatory interactions between human coronary smooth muscle cells and dendritic cells.

Authors:  Sara Paccosi; Claudia Musilli; Roberto Caporale; Anna Maria Grazia Gelli; Daniele Guasti; Ann Maria Clemente; Maria Gabriella Torcia; Amelia Filippelli; Paolo Romagnoli; Astrid Parenti
Journal:  PLoS One       Date:  2014-06-16       Impact factor: 3.240

8.  INNAMORA, a European Workshop focussed on the mechanisms of innate immunity in pathogen-host interaction and their exploitation in novel mucosal immunisation strategies.

Authors:  Diana Boraschi; Aldo Tagliabue; Michael U Martin; Rino Rappuoli
Journal:  Vaccine       Date:  2003-06-01       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.